CVRx, Inc. Overview
Pro stress-test →CVRx is a commercial-stage medical device company focused on baroreceptor neuromodulation therapy to treat cardiovascular diseases, primarily heart failure and hypertension. The company's proprietary Barostim platform is an FDA-approved implantable device that uses electrical stimulation to restore autonomic nervous system balance, addressing a large unmet market need in cardiovascular disease management.
Strategic Profile
Pro stress-test →CVRx holds a first-mover advantage as the first FDA-approved neuromodulation therapy for heart failure, creating a defensible market position. The company is expanding clinical evidence through landmark trials like BENEFIT-HF while scaling commercialization in the U.S. market, with revenue generation tied directly to implant volumes and territorial expansion.
Competitive Landscape
Pro stress-test →CVRx operates in the specialty cardiovascular device market against established players and emerging competitors. Competitors include device manufacturers like JenaValve Technology, Medtronic, and iRhythm Technologies. CVRx's differentiation lies in its proprietary neuromodulation approach and FDA-approved status, though it faces longer-term competition from larger medtech companies entering the neuromodulation space.
Industry Context
CVRx, Inc. operates in Medical Devices - Neuromodulation/Cardiovascular.
Key facts
Founded: 2001 · Headquarters: Minneapolis, MN · Employees: 206 · Revenue: $56M · Market cap: $278M